Resistant forms of breast cancer that over-expresses EGFR and HER2/neu often are less vulnerable to the cytotoxic properties of chemotherapeutics due to simultaneous over-expression of transmembrane P-glycoprotein[142–147]. The gene discussed is ERBB2; the disease is breast carcinoma.